<DOC>
	<DOCNO>NCT00967824</DOCNO>
	<brief_summary>RATIONALE : Evaluating decision aid describe risk benefit take tamoxifen citrate prevent breast cancer may helpful woman increase risk breast cancer . PURPOSE : This randomized phase I/II trial study tamoxifen citrate decision aid woman increase risk breast cancer .</brief_summary>
	<brief_title>Tamoxifen Citrate Decision Aids Women Increased Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To develop test decision aid describe risk benefit take tamoxifen citrate prevent primary breast cancer woman increase risk breast cancer . OUTLINE : - Phase I : Patients randomize view 1 16 decision aid vary term information present base 5 dimension : 1 ) statistical information pictograph v plain text , 2 ) risk information present denominator 100 v 1000 , 3 ) risk information present term total vs additional risk , 4 ) whether risk tamoxifen citrate present benefit present , 5 ) contextual information risk patient face ( cause mortality , colon cancer , heart attack ) . Patients complete baseline post-test questionnaire . - Phase II : Patients randomize 1 3 arm . - Arm I ( control ) : Patients view decision aid , complete baseline post-test questionnaire . - Arm II ( control ) : Patients complete baseline questionnaire . They view decision aid complete post-test questionnaire . - Arm III ( intervention ) : Patients view 1 16 decision aid vary base 5 factor : 1 ) providing ( ) comparative information average woman 's breast cancer risk , 2 ) sequence presentation risk benefit ( risk first vs benefit first ) , 3 ) include ( ) summary table follow presentation risk benefit , 4 ) use second vs third person language ( `` risk '' v `` person like '' ) , 5 ) present decision 2 v 3 option ( taking/not take breast cancer prevention drug v take tamoxifen citrate/raloxifene , drug ) . Patients also complete baseline post-test questionnaire . Patients phase complete online follow-up survey 3 month . Patients arm I II ( phase II ) receive decision aid completion follow-up survey .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Believed increase risk breast cancer ( risk â‰¥ 1.66 % 5 year ) accord electronicbased medical data PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>breast cancer</keyword>
</DOC>